Featured Investment Ideas
- Medivation’s Competitor Was Just Acquired, but It’s Not as Bad As It Sounds
By Ivan Deryugin · Wed, Jun 19
Shares of Medivation (MDVN) fell sharply on Monday June 17, closing down over 6% on news that Johnson Johnson (JNJ) has acquired Aragon Pharmaceuticals for $1 billion ($650 million upfront with $350 million in potential milestones). The deal unnerved many investors, who view Aragon and ARN-509, its · more »
- Eight Trade Ideas and A Recap of our Latest
By Editorial Staff · Fri, Jun 14 - Pharmacyclics’ Recent Selloff Was Wrong: Here’s Why We’re Involved
By Ivan Deryugin · Fri, Jun 14 - Bull, Bear, or Indifferent: Profiting From Amarin’s Latest
By Jake King · Tue, Jun 11
Latest News
- Wall Street Initiation on Synergy Pharma Gets The Stock Moving
By Jake King · Mon, Jun 17 - Good News for this Small-Cap Biotech: Eli Lilly Wants to Develop its Diabetes Drug
By Jake King · Mon, Jun 17 - Liquidity and a Discounted Deal Aren’t Ideal for this Chancy Biotech Equity
By Jake King · Mon, Jun 17 - Questcor: The Bear Theses Continue to Unravel
By Jake King · Wed, Jun 12
- Infinity Pharma’s Safety Concerns: For Patient Investors, a Buying Opportunity
By Ivan Deryugin · Mon, Jun 10 - The Market Likes Endo Health’s New Strategy: You Should Too
By Jake King · Thu, Jun 6 - Zogenix Is Having a Hard Time with its Capital Needs
By Jake King · Wed, Jun 5 - Knee-Jerk Market Reaction to BioMarin Data Undue
By Jake King · Tue, Jun 4
Most Popular
- Medivation’s Competitor Was Just Acquired, but It’s Not as Bad As It Sounds
By Ivan Deryugin · Wed, Jun 19 - Wall Street Initiation on Synergy Pharma Gets The Stock Moving
By Jake King · Mon, Jun 17 - Good News for this Small-Cap Biotech: Eli Lilly Wants to Develop its Diabetes Drug
By Jake King · Mon, Jun 17 - Eight Trade Ideas and A Recap of our Latest
By Editorial Staff · Fri, Jun 14
- Pharmacyclics’ Recent Selloff Was Wrong: Here’s Why We’re Involved
By Ivan Deryugin · Fri, Jun 14 - Questcor: The Bear Theses Continue to Unravel
By Jake King · Wed, Jun 12 - Bull, Bear, or Indifferent: Profiting From Amarin’s Latest
By Jake King · Tue, Jun 11 - The Wrap-Up: PropThink’s Top Picks this Week
By Editorial Staff · Fri, Jun 7
